Distinct retinal vessel atrophy patterns may be associated with multiple sclerosis (MS), but further research is needed to assess retinal vessel changes and their underlying role in MS. Changes in the ...

Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt ...

Please provide your email address to receive an email when new articles are posted on . Science Corporation reported positive preliminary results of a clinical trial examining its Prima retinal ...

Regardless of dosing regimen, patients treated with ranibizumab had a 43% higher incidence of GA, which was a statistically significant increase compared with bevacizumab. The ranibizumab group had ...

A recent retrospective cross-sectional observational study concluded that the Medios AI system, in conjunction with the Remidio smartphone-based fundus camera, has strong potential to ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

OCU410 has a very favorable safety and tolerability profile No serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular ...

Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on ...

Add Yahoo as a preferred source to see more of our stories on Google. José-Alain Sahel, M.D., holding the PRIMA implant. (CREDIT: UPMC) A small wireless chip and a pair of smart glasses are offering ...